|Bid||15.87 x 800|
|Ask||18.00 x 2200|
|Day's Range||15.51 - 18.44|
|52 Week Range||6.30 - 18.44|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.71|
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.
While not a mind-blowing move, it is good to see that the Arcus Biosciences, Inc. (NYSE:RCUS) share price has gained...
Does Arcus Biosciences, Inc. (NYSE:RCUS) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -8.51% and 30.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -72.97% and -61.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Eric Hoefer has joined the Company as Chief Commercial Officer. Mr. Hoefer will oversee all aspects of the Company’s global commercial strategy and operations as the Company works to ensure that it most efficiently leverages the clinical and market development opportunities for its therapeutic candidates.